Your cart is empty
This topical reference and handbook addresses the chemistry,
pharmacology, toxicology and the patentability of prodrugs,
perfectly mirroring the integrated approach prevalent in today's
drug design. It summarizes current experiences and strategies for
the rational design of prodrugs, beginning at the early stages of
the development process, as well as discussing organ- and
"This book covers the unique application of flow cytometry in drug discovery and development. The first section includes two introductory chapters, one on flow cytometry and one on biomarkers, as well as a chapter on recent advances in flow cytometry. The second section focuses on the unique challenges and added benefits associated with the use of flow cytometry in the drug development process. The third section contains a single chapter presenting an in depth discussion of validation considerations and regulatory compliance issues associated with drug development"--Provided by publisher.
"Biofilm Eradication and Prevention"s presents the basics of biofilm formation on medical devices, diseases related to this formation, and approaches pharmaceutical researchers need to take to limit this problem. Split into three parts, the first deals with the development and characterization of biofilm on the surfaces of implanted or inserted medical devices. Questions as to why biofilms form over medical device surfaces and what triggers biofilm formation are addressed. In the second section, the author discusses biofilm-mediated chronic infections occurred in various organs (eyes, mouth, wounds) and pharmaceutical and drug delivery knowledge gained from research in these area. The third part explores pharmaceutical approaches like lipid-and polymer-based drug delivery carriers for eradicating biofilm on device-related infections. In addition, this section also explores the topic of novel small molecule (like iron and its complexes/metal chelators) and a quorum-sensing inhibitors to control medical biofilm formation.
Essential principles and practice of assay development
The first comprehensive, integrated treatment of the subject, Assay Development: Fundamentals and Practices covers the essentials and techniques involved in carrying out an assay project in either a biotechnology/drug discovery setting or a platform setting.
Rather than attempting comprehensive coverage of all assay development technologies, the book introduces the most widely used assay development technologies and illustrates the art of assay development through a few commonly encountered biological targets in assay development (e.g., proteases, kinases, ion channels, and G protein-coupled receptors). Just enough biological background for these biological targets is provided so that the reader can follow the logics of assay development. Chapters discuss:
The basics of assay development, including foundational concepts and applications
Commonly used instrumental methods for both biochemical assays and cell-based assays
Assay strategies for protein binding and enzymatic activity
An in-depth study of the now popular Caliper's off-chip kinase assay provides an instructive, real-world example of the assay development process.
Discover how biomarkers can boost the success rate of drug development efforts
As pharmaceutical companies struggle to improve the success rate and cost-effectiveness of the drug development process, biomarkers have emerged as a valuable tool. This book synthesizes and reviews the latest efforts to identify, develop, and integrate biomarkers as a key strategy in translational medicine and the drug development process. Filled with case studies, the book demonstrates how biomarkers can improve drug development timelines, lower costs, facilitate better compound selection, reduce late-stage attrition, and open the door to personalized medicine.
"Biomarkers in Drug Development" is divided into eight parts:
Part One offers an overview of biomarkers and their role in drug development.
Part Two highlights important technologies to help researchers identify new biomarkers.
Part Three examines the characterization and validation process for both drugs and diagnostics, and provides practical advice on appropriate statistical methods to ensure that biomarkers fulfill their intended purpose.
Parts Four through Six examine the application of biomarkers in discovery, preclinical safety assessment, clinical trials, and translational medicine.
Part Seven focuses on lessons learned and the practical aspects of implementing biomarkers in drug development programs.
Part Eight explores future trends and issues, including data integration, personalized medicine, and ethical concerns.
Each of the thirty-eight chapters was contributed by one or more leading experts, including scientists from biotechnology and pharmaceutical firms, academia, and the U.S. Food and Drug Administration. Their contributions offer pharmaceutical and clinical researchers the most up-to-date understanding of the strategies used for and applications of biomarkers in drug development.
Leading experts illustrate how sophisticated computational data mining techniques can impact contemporary drug discovery and development
In the era of post-genomic drug development, extracting and applying knowledge from chemical, biological, and clinical data is one of the greatest challenges facing the pharmaceutical industry. Pharmaceutical Data Mining brings together contributions from leading academic and industrial scientists, who address both the implementation of new data mining technologies and application issues in the industry. This accessible, comprehensive collection discusses important theoretical and practical aspects of pharmaceutical data mining, focusing on diverse approaches for drug discovery--including chemogenomics, toxicogenomics, and individual drug response prediction. The five main sections of this volume cover: A general overview of the discipline, from its foundations to contemporary industrial applicationsChemoinformatics-based applicationsBioinformatics-based applicationsData mining methods in clinical developmentData mining algorithms, technologies, and software tools, with emphasis on advanced algorithms and software that are currently used in the industry or represent promising approaches
In one concentrated reference, Pharmaceutical Data Mining reveals the role and possibilities of these sophisticated techniques in contemporary drug discovery and development. It is ideal for graduate-level courses covering pharmaceutical science, computational chemistry, and bioinformatics. In addition, it provides insight to pharmaceutical scientists, principal investigators, principal scientists, research directors, and all scientists working in the field of drug discovery and development and associated industries.
Offering a conceptual and factual presentation of the metabolism of
drugs and other xenobiotics, these two volumes distinctly focus on
the biochemistry, with an emphasis on xenobiotic-metabolizing
enzymes, their reactions and regulations.
The first edition of Pharmaceutical Extrusion Technology, published in 2003, was deemed the seminal book on pharmaceutical extrusion. Now it is expanded and improved, just like the usage of extrusion has expanded, improved and evolved into an accepted manufacturing technology to continuously mix active pharmaceutical ingredients with excipients for a myriad of traditional and novel dosage forms. Pharmaceutical Extrusion Technology, Second Edition reflects how this has spawned numerous research activities, in addition to hardware and process advancements. It offers new authors, expanded chapters and contains all the extrusion related technical information necessary for the development, manufacturing, and marketing of pharmaceutical dosage forms.
This book gives you an updated and expert overview of nuclear hormone receptors in drug metabolism and drug development and equips you with the interdisciplinary understanding of these receptors and how they can be regulated. Pharmaceutical researchers will find this extremely useful in developing drugs for cancer, heart disease, and diabetes treatment. This comprehensive resource collects scattered materials into one handy, informative volume.
"The goal is to provide a comprehensive reference book for the
preclinicaldiscovery and development scientist whose
responsibilities span target identification, lead candidate
selection, pharmacokinetics, pharmacology, and toxicology, and for
regulatory scientists whose responsibilities include the evaluation
of novel therapies."
This handbook compiles comprehensive reference information on sweeteners for academic researchers and professionals. It discusses both natural as well as synthetic products, considering health-related and economical aspects. Renowned authors mostly from academia, but also from the industry, summarize information about the chemistry, biological and pharmacological aspects, as well as bioavailability and applications of sweeteners. The book introduces various substance classes of sweeteners, which are mainly plant-derived, including glycosidic and terpenoid sweeteners, peptidic sweeteners, sweet-tasting proteins and protein-derived sweeteners (e.g. stevioside, sucralose, aspartame, thaumatin, brazzein and many more). Chapters address topics such as the isolation and purification of the compounds, their physical, chemical and biological properties, pharmacological activities, and also critically discuss their applications in view of health and ecotoxicological aspects. A special emphasis is on low or no-calorie sweeteners, for which there is an increasing demand and intensified research activities currently. This reference work hence provides the readers with key information and will serve the needs of graduate students and scholars, researchers and professionals working in the fields of chemistry, botany, biotechnology, or pharmacological or agricultural research, as well as in the food industry or the marketing of sweeteners.
Drug design is the approach of finding drugs by design, based on their biological targets. Typically a drug target is a key molecule involved in a particular metabolic or signalling pathway that is specific to a disease condition or pathology, or to the infectivity or survival of a microbial pathogen. Some approaches attempt to stop the functioning of the pathway in the diseased state by causing a key molecule to stop functioning. Drugs may be designed that bind to the active region and inhibit this key molecule. However these drugs would also have to be designed in such a way as not to affect any other important molecules that may be similar in appearance to the key molecules. Sequence homologies are often used to identify such risks. Other approaches may be to enhance the normal pathway by promoting specific molecules in the normal pathways that may have been affected in the diseased state. The structure of the drug molecule that can specifically interact with the biomolecules can be modelled using computational tools. These tools can allow a drug molecule to be constructed within the biomolecule using knowledge of its structure and the nature of its active site. Construction of the drug molecule can be made inside out or outside in depending on whether the core or the R-groups are chosen first. However many of these approaches are plagued by the practical problems of chemical synthesis. Newer approaches have also suggested the use of drug molecules that are large and proteinaceous in nature rather than as small molecules. There have also been suggestions to make these using mRNA. Gene silencing may also have therapeutical applications. This book presents leading-edge research from around the world.
The definitive guide to peptidomics- a hands-on lab reference
Drug discovery for influenza antivirals
Post Genomics Drug Discovery and Research explores and discusses some of the most important topics in post-genomics life and biopharmaceutical sciences. It provides an introduction to the field, outlining examples of many techniques currently used, as well as those still under development, which are important for the research of biopharmaceutical discovery in the post-genomics era.* Integrates several developing and cutting-edge technologies and methods like bioinformatics, experimental therapeutics, and molecular recognition* Includes discussion on topics such as: computer-aided ligand design; peptide and protein chemistry and synthesis; synthesis of active natural products; and the use of emerging technologies like proteomics, nanotechnology, or bioengineering.
This book deals with evolving intelligence systems and their use in immune algorithm (IM), particle swarm optimization (PSO), bacterial foraging (BF), and hybrid intelligent system to improve plants, robots, etc. It discusses the motivation behind research on and background of evolving intelligence systems and illustrates IM-based approach for parameter estimation required for designing an intelligent system. It approaches optimal intelligent tuning using a hybrid genetic algorithm-particle swarm optimization (GA-PSO) and illustrates hybrid GA-PSO for intelligent tuning of vector system.
Advances in genomics and combinatorial chemistry during the past two decades inspired innovative technologies and changes in the discovery and pre-clinical development paradigm with the goal of accelerating the process of bringing therapeutic drugs to market. Written by William Kisaalita, one of the foremost experts in this field, 3D Cell-Based Biosensors in Drug Discovery Programs: Microtissue Engineering for High Throughput Screening provides the latest information - from theory to practice - on challenges and opportunities for incorporating 3D cell-based biosensors or assays in drug discovery programs. The book supplies a historical perspective and defines the problem 3D cultures can solve. It also discusses how genomics and combinatorial chemistry have changed the way drug are discovered and presents data from the literature to underscore the less-than-desirable pharmaceutical industry performance under the new paradigm. The author uses results from his lab and those of other investigators to show how 3D micro environments create cell culture models that more closely reflect normal in vivo-like cell morphology and function. He makes a case for validated biomarkers for three-dimensionality in vitro and discusses the advantages and disadvantages of promising tools in the search of these biomarkers. The book concludes with case studies of drugs that were abandoned late in the discovery process, which would have been discarded early if tested with 3D cultures. Dr. Kisaalita presents evidence in support of embracing 3D cell-based systems for widespread use in drug discovery programs. He goes to the root of the issue, establishing the 3D cell-based biosensor physiological relevance by comparing 2D and 3D culture from genomic to functional levels. He then assembles the bioengineering principles behind successful 3D cell-based biosensor systems. Kisaalita also addresses the challenges and opportunities for incorporating 3D cell-based biosensors or cultures in current discovery and pre-clinical development programs. This book makes the case for widespread adoption of 3D cell-based systems, rendering their 2D counterparts, in the words of Dr. Kisaalita "quaint, if not archaic" in the near future.
Enables researchers to fully realize the potential to discover new pharmaceuticals among heterocyclic compounds
Integrating heterocyclic chemistry and drug discovery, this innovative text enables readers to understand how and why these two fields go hand in hand in the effective practice of medicinal chemistry. Contributions from international leaders in the field review more than 100 years of findings, explaining their relevance to contemporary drug discovery practice. Moreover, these authors have provided plenty of practical guidance and tips based on their own academic and industrial laboratory experience, helping readers avoid common pitfalls.
"Heterocyclic Chemistry in Drug Discovery" is ideal for readers who want to fully realize the almost limitless potential to discover new and effective pharmaceuticals among heterocyclic compounds, the largest and most varied family of organic compounds. The book features: Several case studies illustrating the role and application of 3, 4, 5, and 6+ heterocyclic ring systems in drug discoveryStep-by-step descriptions of synthetic methods and practical techniquesExamination of the physical properties for each heterocycle, including NMR data and quantum calculationsDetailed explanations of the complexity and intricacies of reactivity and stability for each class of heterocycles
"Heterocyclic Chemistry in Drug Discovery" is recommended as a textbook for organic and medicinal chemistry courses, particularly those emphasizing heterocyclic chemistry. The text also serves as a guide for medicinal and process chemists in the pharmaceutical industry, offering them new insights and new paths to explore for effective drug discovery.
A case history approach to drug synthesis and discovery
Discover the origins of some of today's most popular drug therapies. Explore case histories and gain insight into major classes of antibiotics, antiviral drugs, analgesics, steroids, compounds designed to lower cholesterol, and more. Review the steps required for FDA approval. This is a great reference for students in medicinal chemistry, researchers in pharmaceuticals, and medical practitioners.
The state of the art in biopharmaceutical FUSION PROTEIN DESIGN
Fusion proteins belong to the most lucrative biotech drugs--with Enbrel(R) being one of the best-selling biologics worldwide. Enbrel(R) represents a milestone of modern therapies just as Humulin(R), the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone(R) the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protein was launched.
"Fusion Protein Technologies for Biopharmaceuticals" examines the state of the art in developing fusion proteins for biopharmaceuticals, shedding light on the immense potential inherent in fusion protein design and functionality. A wide pantheon of international scientists and researchers deliver a comprehensive and complete overview of therapeutic fusion proteins, combining the success stories of marketed drugs with the dynamic preclinical and clinical research into novel drugs designed for as yet unmet medical needs.
The book covers the major types of fusion proteins--receptor-traps, immunotoxins, Fc-fusions and peptibodies--while also detailing the approaches for developing, delivering, and improving the stability of fusion proteins. The main body of the book contains three large sections that address issues key to this specialty: strategies for extending the plasma half life, the design of toxic proteins, and utilizing fusion proteins for ultra specific targeting. The book concludes with novel concepts in this field, including examples of highly relevant multifunctional antibodies.
Detailing the innovative science, commercial realities, and brilliant potential of fusion protein therapeutics, "Fusion Protein Technologies for Biopharmaceuticals" is a must for pharmaceutical scientists, biochemists, medicinal chemists, molecular biologists, pharmacologists, and genetic engineers interested in determining the shape of innovation in the world of biopharmaceuticals.
The Life-Cycle of Pharmaceuticals in the Environment identifies pathways of entry of pharmaceuticals into the environment, beginning with the role of global prescribing and disposal practices. The book then discusses typical levels of common pharmaceuticals and how they can be determined in natural waters such as raw and treated sewage, and in potable water. In addition, sections examine methods currently available to degrade pharmaceuticals in natural waters and some of their ecotoxicological impacts, along with future considerations and the growing concept of product stewardship.
Facilitates the discovery and development of new, effective therapeutics
With coverage of the latest mass spectrometry technology, this book explains how mass spectrometry can be used to enhance almost all phases of drug discovery and drug development, including new and emerging applications. The book's fifteen chapters have been written by leading pharmaceutical and analytical scientists. Their contributions are based on a thorough review of the current literature as well as their own experience developing new mass spectrometry techniques to improve the ability to discover and develop new and effective therapeutics.
"Mass Spectrometry for Drug Discovery and Drug Development" begins with an overview of the types of mass spectrometers that facilitate drug discovery and development. Next it covers: HPLC-high-resolution mass spectrometry for quantitative assaysMass spectrometry for siRNAQuantitative analysis of peptidesMass spectrometry analysis of biological drugsApplications that support medicinal chemistry investigationsMass spectrometry imaging and profiling
Throughout the book, detailed examples underscore the growing role of mass spectrometry throughout the drug discovery and development process. In addition, images of mass spectra are provided to explain how results are interpreted. Extensive references at the end of each chapter guide readers to the primary literature in the field.
"Mass Spectrometry for Drug Discovery and Drug Development" is recommended for readers in pharmaceutics, including medicinal chemists, analytical chemists, and drug metabolism scientists. All readers will discover how mass spectrometry can streamline and advance new drug discovery and development efforts.
You may like...
Metabolism of Drugs and Other…
Pavel Anzenbacher, Ulrich M. Zanger Hardcover
Lead Generation - Methods and Strategies
Jorg Holenz, Markus Haeberlein Hardcover
The The Biochemistry of Drug Metabolism…
Bernard Testa, Stefanie D. Kramer Paperback
Pharmaceutical Salts - Properties…
P.Heinrich Stahl, Camille Georges Wermuth Hardcover
Pharmacological Basis of Acute Care
Yoo Kuen Chan, Kwee Peng Ng, … Hardcover
Parasitic Helminths - Targets, Screens…
Conor R. Caffrey Hardcover
Host - Pathogen Interaction - Microbial…
Gottfried Unden, Eckhard Thines, … Hardcover
Scaffold Hopping in Medicinal Chemistry
Nathan Brown Hardcover
Medicinal Chemistry Approaches to…
Karen Lackey, Bruce Roth Hardcover
Trypanosomatid Diseases - Molecular…
Timo Jager, Oliver Koch, … Hardcover